Claims

1. A compound having the general formula I:



Formula I

wherein

n is 0 or 1;

X^1 and X^2 are independently, at each occurrence, CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^1 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkoxy, $-NH_2$, $-NHR^6$, $-NR^7R^8$ and $-NH-(R^9)_n-R^{10}$, n being 0 or 1;

R^2 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl,$-NH_2$, $-NHR^6$, $-NR^7R^8$ and $-NH-(R^9)_n-R^{10}$ group, n being 0 or 1;

with the proviso that R^1 and R^2 are not hydrogen at the same time,

R^3 is selected from the group consisting of OR^{11}, $-NR^7R^8$, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_3 haloalkyl,$-C(O)NHR^{11}$, aryl, and heteroaryl group, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^4 is selected from the group consisting of $-N(R^{12})(V)_pR^{13}$, $-NH(V)_p-OR^{14}$, $-NHC(O)R^{15}$, and groups of formula Ia shown below,



Formula Ia

wherein,
p is 0 or 1,
V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_3 alkyl, C_3-C_6 cycloalkyl or phenyl groups, or wherein a carbon atom of said alkylene forms part of a C_3-C_6 cycloalkyl group;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^6 is selected from the group consisting of C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_6 haloalkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^7 and R^8 are independently, at each occurrence, C_1-C_6 alkyl or heterocyclyl; or
R^7 and R^8 are connected to each other to make a four, five or six membered heterocyclyl or heteroaryl group, wherein each of said heterocyclyl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^9 is C_1-C_4 alkylene, wherein said alkylene is optionally substituted with one to three C_1-C_3 alkyl groups;
R^{10} is selected from the group consisting of hydroxyl, -OR^{11}, -CN, -$C(O)OR^{18}$, -$C(O)NH_2$, -$C(NH)NH_2$, aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{11} is independently, at each occurrence, selected from the group consisting of aryl, e.g. phenyl or benzyl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{12} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_4 alkyl-hydroxyl and C_1-C_4 alkyl-alkoxy;

R^{13} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkyl-hydroxyl, -OH, -C(O)NH_2, -C(O)OR^{18}, -CN, C_1-C_3 haloalkyl and heterocyclyl, and groups of formula Ib shown below,



Formula Ib

wherein,

n is 0 or 1;

A^1 is -O-, -CH_2O-, -OCH_2-, -S-, -SO_2-, -SO_2NH-, -C(O)-, -C(O)NH-, -C(O)N(R^7)-, -CH(OH)-, -CH(OR^7)-, -NH-, -N(CH_3)- or -N(CH_2COOR^7)-;

A^2 is –O- or NH-;

B is selected from the group consisting of aryl, e.g. phenyl or benzyl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{15} is aryl, wherein aryl is optionally substituted with one to four halogen groups;

R^{16} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl and hydroxyl ;

R^{17} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, -C(O)R^{11}, -C(O)NHR^{11}, -OR^{11} and aryl , wherein each of said alkyl and aryl is optionally and independently substituted with one to four R^a groups;

R^{18} is hydrogen or C_1-C_6 alkyl;

R^{19} is selected from the group consisting of hydrogen, -OR^{22} and -CH_2OR^{22};

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, –C(O)R^a and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl group;

R^{22} is selected from the group consisting of C_1-C_6 haloalkyl, aryl, e.g. phenyl or benzyl, and heteroaryl, wherein each of said haloalkyl, aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, –CH_2OR^c, –OCH_2R^c, -OR^c, -CN, NO_2, -N$R^b$$R^c$, -C(O)N$R^b$$R^c$, -C(NH)$NH_2$, -C(O)$R^c$, -C(O)O$R^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl, e.g. phenyl, benzyl, wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, -C(O)NH_2, -COOH, -CO_2Et and heteroaryl;

R^b and R^c are independently, at each occurrence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, aryl, e.g. phenyl

or benzyl, heteroaryl, and heterocyclyl wherein each of said alkyl, cycloalkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2, -COOH, -COOMe, -COOEt, -CN, -NO_2, -NH_2; or

R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 having the general formula II:



Formula II

wherein

n is 0 or 1;

X^1 is CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^{23} is selected from the group consisting of C_1-C_6 alkyl, C_1-C_3 haloalkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{24} is selected from the group consisting of hydrogen, C_3-C_{10}cycloalkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{25} is selected from the group consisting of $-(V)_pR^{26}$ and $-(V)_p-OR^{14}$;

wherein,

p is 0 or 1,

V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_3 alkyl or phenyl groups, or wherein a carbon atom of said alkylene forms part of a C_3-C_6 cycloalkyl group;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{26} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, -CN and C_1-C_3 haloalkyl, and groups of formula IIa shown below,



Formula IIa

wherein,

A^2 is -O- or NH-;

A^3 is -O-, $-CH_2O-$, $-OCH_2^-$, or –NH-;

B is selected from the group consisting of aryl, e.g. phenyl or benzyl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{19} is selected from the group consisting of hydrogen, $-OR^{22}$ and $-CH_2OR^{22}$;

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl;

R^{22} is selected from the group consisting of aryl, e.g. phenyl or benzyl, and heteroaryl, wherein each of said aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, $–CH_2OR^c$, $–OCH_2R^c$, $-OR^c$, -CN, NO_2, $-NR^bR^c$, $-C(O)NR^bR^c$, $-C(NH)NH_2$, $-C(O)R^c$, $-C(O)OR^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl, e.g. phenyl, benzyl, wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, $-C(O)NH_2$, -COOH, $-CO_2Et$ and heteroaryl;

R^b and R^c are independently, at each occurence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, aryl, e.g. phenyl or benzyl, heteroaryl, and heterocyclyl wherein each of said alkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, $-C(O)NH_2$, -COOH, -COOMe, -COOEt, -CN, $-NO_2$, $-NH_2$; or
R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;
and pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 having the general formula III:



Formula III

wherein

n is 0 or 1;

X^1 is CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^{23} is selected from the group consisting of C_1-C_6 alkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{27} is selected from the group consisting of hydrogen, -R^6, and -R^9-R^{10} ;

wherein,

R^6 is selected from the group consisting of C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_6 haloalkyl, aryl, heteroaryl and heterocyclyl group, wherein said alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^9 is C_1-C_4 alkylene, wherein said alkylene is optionally substituted with one to three C_1-C_3 alkyl groups;

R^{10} is selected from the group consisting of hydroxyl, $-OR^{11}$, $-C(O)OR^{18}$, $-C(O)NH_2$, aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{11} is independently, at each occurrence selected from the group consisting of aryl, e.g. phenyl or benzyl, heteroaryl and heterocyclyl group wherein said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{18} is hydrogen or C_1-C_6 alkyl;

R^{28} is selected from the group consisting of $-(V)_pR^{29}$ and $-(V)_p$-OR^{14} group;

wherein,

p is 0 or 1,

V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_6 alkyl or phenyl groups;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{29} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and C_1-C_3 haloalkyl, and groups of formula IIIa shown below,



Formula IIIa

wherein,

A^2 is -O- or NH-;

A^3 is -O-, -CH_2O-, -OCH_2-, or –NH-;

B is selected from the group consisting of aryl, e.g. phenyl or benzyl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{19} is selected from the group consisting of hydrogen, -OR^{22} and -CH_2OR^{22} ;

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl;

R^{22} is selected from the group consisting of aryl, e.g. phenyl or benzyl, and heteroaryl, wherein said aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, –CH_2OR^c, –OCH_2R^c, -OR^c, -CN, NO_2, -NR^bR^c, -$C(O)NR^bR^c$, -$C(NH)NH_2$, -$C(O)R^c$, -$C(O)OR^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl, e.g. phenyl, benzyl, wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, -$C(O)NH_2$, -COOH, -CO_2Et and heteroaryl;

R^b and R^c are independently, at each occurrence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, aryl, e.g. phenyl or benzyl, heteroaryl, and heterocyclyl wherein each of said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen,

C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2,
-COOH, -COOMe , -COOEt, -CN, -NO_2, -NH_2; or
R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;
and pharmaceutically acceptable salts thereof.

4. The compound according to any of claims 1-3, having one of the formulae 1- 556, as shown in table below

No.	Structure
1	
2	
3	
4	
5	
6	
7	

8	
9	
10	
11	
12	
13	
14	
15	
16	

17	
18	
19	
20	
21	
22	
23	
24	
25	

26	
27	
28	
29	
30	
31	
32	
33	
34	
35	

36	
37	
38	
39	
40	
41	
42	
43	
44	

45	
46	
47	
48	
49	
50	
51	
52	
53	
54	

55	
56	
57	
58	
59	
60	
61	
62	
63	
64	

65	
66	
67	
68	
69	
70	
71	
72	
73	
74	

75	
76	
77	
78	
79	
80	
81	
82	
83	

84	
85	
86	
87	
88	
89	
90	
91	

92	
93	
94	
95	
96	
97	
98	
99	

100	
101	
102	
103	
104	
105	
106	
107	

108	
109	
110	
111	
112	
113	
114	
115	

116	
117	
118	
119	
120	
121	
122	
123	

124	
125	
126	
127	
128	
129	
130	
131	

132	
133	
134	
135	
136	
137	
138	
139	

140	
141	
142	
143	
144	
145	
146	
147	

148	
149	
150	
151	
152	
153	
154	
155	

156	
157	
158	
159	
160	
161	
162	
163	

164	
165	
166	
167	
168	
169	
170	
171	

172	
173	
174	
175	
176	
177	
178	
179	

180	
181	
182	
183	
184	
185	
186	
187	

188	
189	
190	
191	
192	
193	
194	
195	

196	
197	
198	
199	
200	
201	
202	
203	

204	
205	
206	
207	
208	
209	
210	
211	

212	
213	
214	
215	
216	
217	
218	
219	

220	
221	
222	
223	
224	
225	
226	
227	

228	
229	
230	
231	
232	
233	
234	
235	

236	
237	
238	
239	
240	
241	
242	
243	

244	
245	
246	
247	
248	
249	
250	
251	

252	
253	
254	
255	
256	
257	
258	
259	

260	
261	
262	
263	
264	
265	
266	
267	

268	
269	
270	
271	
272	
273	
274	
275	

276	
277	
278	
279	
280	
281	
282	
283	

284	
285	
286	
287	
288	
289	
290	
291	

292	
293	
294	
295	
296	
297	
298	
299	

300	
301	
302	
303	
304	
305	
306	
307	

308	
309	
310	
311	
312	
313	
314	
315	

316	
317	
318	
319	
320	
321	
322	
323	

324	
325	
326	
327	
328	
329	
330	
331	

332	
333	
334	
335	
336	
337	
338	
339	

340	
341	
342	
343	
344	
345	
346	
347	

348	
349	
350	
351	
352	
353	
354	
355	

356	
357	
358	
359	
360	
361	
362	
363	

364	
365	
366	
367	
368	
369	
370	
371	

372	
373	
374	
375	
376	
377	
378	
379	

380	
381	
382	
383	
384	
385	
386	
387	

388	
389	
390	
391	
392	
393	
394	
395	

396	
397	
398	
399	
400	
401	
402	

403	
404	
405	
406	
407	
408	
409	
410	

411	
412	
413	
414	
415	
416	
417	
418	

419	
420	
421	
422	
423	
424	
425	
426	

427	
428	
429	
430	
431	
432	
433	
434	

435	
436	
437	
438	
439	
440	
441	
442	

443	
444	
445	
446	
447	
448	
449	
450	

451	
452	
453	
454	
455	
456	
457	

458	
459	
460	
461	
462	
463	
464	
465	

466	
467	
468	
469	
470	
471	
472	
473	

474	
475	
476	
477	
478	
479	
480	
481	

482	
483	
484	
485	
486	
487	
488	
489	

490	
491	
492	
493	
494	
495	
496	
497	

498	
499	
500	
501	
502	
503	
504	
505	

506	
507	
508	
509	
510	
511	
512	
513	

514	
515	
516	
517	
518	
519	
520	
521	

522	
523	
524	
525	
526	
527	
528	

529	
530	
531	
532	
533	
534	
535	

536	
537	
538	
539	
540	
541	
542	

543	
544	
545	
546	
547	
548	
549	

550	
551	
552	
553	
554	
555	
556	

; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein R^4 is $–N(R^{12})(V)_pR^{13}$, R^{12} is H, V is C_1-alkylene, p is 1, R^{13} is



and B is heteroaryl which is optionally substituted with one to four R^a groups**.**

6. The compound according to any of claims 1 or 5 wherein R^1 is $–NH_2$ or $–NHR^6$, R^6 is heteroaryl or heterocyclyl wherein each of said heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups.

7. The compound according to any of claims 1- 6 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with the 5LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, said disease being selected from inflammatory diseases, e.g. asthma, atherosclerosis, pain, or COPD, cancer, stroke and Alzheimer's disease.

8. The compound according to any of claims 1- 7, wherein said compound has an inhibitory activity on an enzyme involved in an inflammatory pathway or several inflammatory pathways, e.g. the arachidonate 5-lipoxygenese pathway and/or the prostaglandin E synthase pathway, preferably on arachidonate 5-lipoxygenase (5-lipoxygenase, 5-LO, 5-LOX, Alox5), at a concentration of said compound between 0.001-50μM, particularly preferably having an IC_{50} on arachidonate 5-lipoxygenase of less than 1μM and/or having an EC_{50} of less than 10μM on the production of leukotriene B4 (LTB4) in rat basophilic leucocyte cells (RBL) and/or rat whole blood (RWB), and/or having a 40-70 % inhibitory activity, preferably a>70 % inhibitory activity on the production of prostaglandin E2 in HeLaS3 cells, stimulated with TNF-α, at a concentration of 10μM of said compound.

9. A composition comprising a compound or a pharmaceutically acceptable salt thereof, as defined in any of claims 1- 6, and a pharmaceutically acceptable carrier.

10. The composition according to claim 9, for use in the treatment of a disease associated with the 5LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, said disease being selected from inflammatory diseases, e.g. asthma, atherosclerosis, pain, or COPD, cancer, stroke and Alzheimer's disease.

11. The compound according to claim 8 or compound or composition for use according to any of claims 7 or 10 wherein said inflammatory disease is one or several of asthma, allergic rhinitis, dermatitis, chronic obstructive pulmonary disease (COPD), inflammation post infection, arthritis, atherosclerosis, allergies, such as hay fever, autoimmune diseases, such as lupus erythematosus, inflammatory bowel diseases, such as Crohn's disease, celiac disease, acne, or pain, e.g. inflammatory and/or neuropathic pain.

12. The compound or composition for use according to any of claims 7 and 10-11 wherein a treatment to a patient in need thereof, suffering from an inflammatory disease, and/or of cancer, and/or of stroke, and/or of Alzheimer's disease comprises administering a suitable amount of a compound as defined in any of claims 1-6, or of a composition as defined in claim 9.

13. Use of a suitable amount of a compound as defined in any of claims 1-6 or a composition as defined in claim 9 in the manufacture of a medicament for the treatment of a disease associated with the 5-LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, wherein said disease being selected from inflammatory diseases, cancer and Alzheimer's disease.

14. The use according to claim 13 , wherein said inflammatory disease is selected from asthma, allergic rhinitis, dermatitis, chronic obstructive pulmonary disease (COPD), inflammation post infection, arthritis, atherosclerosis, allergies, such as hay fever, autoimmune diseases, such as lupus erythematosus, inflammatory bowel diseases, such as Crohn's disease, celiac disease, acne, and pain, e.g. inflammatory and/or neuropathic pain.

15. The compound or composition for use according to claim 12 or the use according to any of claims 13-14, wherein said suitable amount is an amount in the range of 0.01mg/kg body weight to 1g/kg body weight of said patient.

16. A compound that competitively inhibits the specific binding of a compound as defined in any of claims 1-6 to arachidonate 5-lipoxygenase (5-lipoxygenase, 5-LO, 5-LOX, Alox5) or to prostaglandin E synthase (PGES).

17. Use of a suitable amount of a compound according to claim 16, in the manufacture of a medicament for the treatment of an inflammatory disease, in particular asthma, atherosclerosis, pain, chronic obstructive pulmonary disease (COPD), inflammation post infection, allergic rhinitis, arthritis, pain, e.g. inflammatory or neuropathic pain, allergies, such as hay fever, autoimmune diseases, such as lupus erythematosus, inflammatory bowel diseases, such as Crohn’s disease, celiac disease, acne, and/or dermatitis, or a method of treatment of cancer/and or of Alzheimer’s disease.

18. The use according to claim 17 wherein said patient is a patient suffering from an inflammatory disease and/or from cancer and/or from stroke and/or from Alzheimer’s disease.